IMMUNITYBIO
NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. They discover and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. The company was incorporated in 2014 and is based in Culver City, California.
IMMUNITYBIO
Industry:
Health Care Health Diagnostics Therapeutics
Founded:
2014-01-01
Address:
Culver City, California, United States
Country:
United States
Website Url:
http://www.immunitybio.com
Total Employee:
101+
Status:
Active
Contact:
(310) 883-1300
Total Funding:
182.66 M USD
Technology used in webpage:
SPF Google Analytics Wordpress Plugins Microsoft Azure DNS US Privacy User Signal Mechanism GoDaddy DNS Cloudflare Person Schema Gravatar Profiles Cloudflare Network Error Logging
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Helomics
Helomics provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services.
Current Employees Featured
Patrick Soon-Shiong Founder @ ImmunityBio
Founder
Barry Simon Director & Chief Corporate Affairs Officer @ ImmunityBio
Director & Chief Corporate Affairs Officer
2021-03-01
Sarah Singleton Chief Communications Officer @ ImmunityBio
Chief Communications Officer
2019-12-01
Helen Luu Chief Commercial Officer @ ImmunityBio
Chief Commercial Officer
Charles Kim General Counsel @ ImmunityBio
General Counsel
Fabio Benedetti Chief Strategy Officer @ ImmunityBio
Chief Strategy Officer
2021-01-01
David Sachs Chief Financial Officer @ ImmunityBio
Chief Financial Officer
2019-07-01
Leonard Sender Chief Operating Officer @ ImmunityBio
Chief Operating Officer
2020-03-01
Patrick Soon-Shiong Executive Chairman of the Board @ ImmunityBio
Executive Chairman of the Board
2021-08-11
Hans Klingemann Chief Science Officer – Cellular @ ImmunityBio
Chief Science Officer – Cellular
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-12-21 | NantKwest | NantKwest acquired by ImmunityBio | N/A |
| 2017-06-27 | Altor BioScience | Altor BioScience acquired by ImmunityBio | 290 M USD |
| 2015-06-23 | VivaBioCell | VivaBioCell acquired by ImmunityBio | N/A |
Investors List
Patrick Soon-Shiong
Patrick Soon-Shiong investment in Private Equity Round - ImmunityBio
Key Employee Changes
Official Site Inspections
http://www.immunitybio.com Semrush global rank: 1.8 M Semrush visits lastest month: 12.68 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ImmunityBio"
Investor Relations - ImmunityBio, Inc.
Apr 15, 2025 ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers …See details»
ImmunityBio is on a Mission
ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious disease. Since then we have progressed into a clinical …See details»
ImmunityBio, Inc. | LinkedIn
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to ...See details»
ImmunityBio - The Org
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it …See details»
ImmunityBio - Crunchbase Company Profile & Funding
ImmunityBio conducts clinical trials to evaluate the safety and efficacy of its investigational therapies for various cancers and diseases. CD19 t-haNK: CD19 t-haNK is a CAR-NK cell therapy targeting CD19, used for treating …See details»
ImmunityBio Announces Execution of $75 Million Equity Financing …
Apr 8, 2025 CULVER CITY, Calif.--(BUSINESS WIRE)--Apr. 8, 2025-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed …See details»
ImmunityBio (IBRX) Company Profile & Description - Stock Analysis
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. …See details»
ImmunityBio - Overview, News & Similar companies - ZoomInfo
Explore Complete Organization Structure. Is ImmunityBio your ideal customer? Let us give you the heads up on whether it's a good time to reach out ... --Immunotherapy innovator …See details»
ImmunityBio Company Profile - Office Locations, Competitors
Oct 29, 2024 ImmunityBio has 4 employees across 3 locations and $14.75 m in annual revenue in FY 2024. See insights on ImmunityBio including office locations, competitors, revenue, …See details»
ImmunityBio Company Profile | Management and Employees List
SQL International Organization for Standardization . Java Oracle . C++ ISO/IEC JTC1/SC22/WG21 - The C++ Standards Committee . Python Python Software Foundation . …See details»
ImmunityBio - VentureRadar
" ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, …See details»
Mission, Vision & Core Values of ImmunityBio
Dec 19, 2024 How Core Values Influence Operations: Guiding decision-making, fostering teamwork, and ensuring ethical practices in all aspects of the organization. Overall Impact of …See details»
ImmunityBio Inc Company Profile - Overview - GlobalData
ImmunityBio Inc (ImmunityBio), a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company that develops innovative treatments for advanced cancers and infectious diseases. …See details»
ImmunityBio Investor Day - ImmunityBio, Inc.
Apr 15, 2025 The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
ImmunityBio, Inc. Information - RocketReach
ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when …See details»
Founder's Vision - ImmunityBio
Founder’s Hypothesis. For the past 35 years, through my experience at UCLA treating both diabetic patients with pancreas transplants, and pancreatic cancer patients with pancreatic …See details»
ImmunityBio Company Overview, Contact Details & Competitors
Jan 1, 2021 ImmunityBio. Biotechnology Research California, United States 501-1000 Employees. ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and …See details»
ImmunityBio: A Vital Approach to Cancer and Infectious Disease
Apr 29, 2025 ImmunityBio is investigating heterologous prime-boost regimens, which involve administering different vaccines sequentially to enhance immune responses. These strategies …See details»
ImmunityBio Announces FDA Submissions of Supplemental BLA …
Mar 31, 2025 Company to Provide Regulatory, Sales, and Platform Updates at Investor Day including: In Q1, the company submitted a supplemental Biologics License Application (sBLA) …See details»
Latest News in Targeted Cell Therapies for Cancer ... - ImmunityBio
May 5, 2025 ImmunityBio’s platform addresses the entire immune system beyond the limitations of chimeric antigen receptor T-cell (CAR-T) therapies and checkpoint inhibitors by activating …See details»